Friday, 25 September 2026European Markets

DISTRI-LAND CERT Stock 9.52% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with DISTRI-LAND CERT (DISL.BR) jumping 9.52% to €230.00 on Tuesday, following the last session's upward trend. BEL 20 dropped 0.14% to €3,620.51, following the last session's upward trend on what was a somewhat negative trend trading session today.

About DISTRI-LAND CERT

Immobiliere Distri-Land NV engages in the issuance of real estate certificates. The company is based in Molenbeek-Saint-Jean, Belgium. Immobiliere Distri-Land NV operates as a subsidiary of KBC Bank NV.

Earnings Per Share

As for profitability, DISTRI-LAND CERT has a trailing twelve months EPS of €7.54.

PE Ratio

DISTRI-LAND CERT has a trailing twelve months price to earnings ratio of 30.5. Meaning, the purchaser of the share is investing €30.5 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, DISTRI-LAND CERT's stock is considered to be oversold (<=20).

More news about DISTRI-LAND CERT (DISL.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com